Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass

Calcified Tissue International

Volumn 61, Issue SUPPL. 1, 1997, Pages

  Gennari, C ^a   Adami, S ^g   Agnusdei, D ^a   Bufalino, L ^b   Cervetti, R ^c   Crepaldi, G ^g   Di Marco, C ^g   Di Munno, O ^g   Fantasia, L ^d   Isaia, G C ^g   Mazzuoli, G F ^g   Ortolani, S ^e   Passeri, M ^g   Serni, U ^f   Vecchiet, L ^g  

^a UNIVERSITY OF SIENA   (Italy)

^b Medical Department   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f USL 10   (Italy)

^g NONE

Author keywords

Bone mass; Ipriflavone; Postmenopausal osteopenia

Indexed keywords

IPRIFLAVONE;

ADULT; BONE MASS; BONE METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; TRABECULAR BONE;

ADMINISTRATION, ORAL; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; COHORT STUDIES; CREATININE; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYPROLINE; ISOFLAVONES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; RADIUS;

EID: 0030791462     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900380     Document Type: Conference Paper

References (23)

1. Brandi ML (1992) Flavonoids: biochemical effects and therapeutic applications. Bone Miner 19:S3-S14
2. Notoya K, Yoshida K, Taketomi S, Yamazaki I, Kumegawa M (1992) Inhibitory effect of ipriflavone on pit formation in mouse unfractionated bone cells. Calcif Tissue Int 51(suppl 1):s3-s6
3. Morita I, Sakaguchi K, Kurachi T, Murota SI (1992) Ipriflavone inhibits murine osteoclast formation in vitro. Calcif Tissue Int 51(suppl 1):s7-s10
4. Bonucci E, Silvestrini G, Ballanti P, Masi L, Franchi A, Bufalino L, Brandi ML (1992) Cytological and ultrastructural investigation of osteoblastic and preosteoclastic cells grown in vitro in the presence of ipriflavone: preliminary results. Bone Miner 19:S15-S25
5. Sziklai I, Ribari O (1985) The effect of flavone treatment on human otosclerotic ossicle organ cultures. Arch Otorhinolaryngol 242:67-70
6. Cheng SL, Zhang SF, Nelson TL, Warlow PM, Civitelli R (1994) Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif Tissue Int 55:356-362
7. Kakai Y, Kawase T, Nakano T, Mikuni-Takagaki Y, Saito S (1992) Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif Tissue Int 51(suppl 1):s11-s15
8. Agnusdei D, Camporeale A, Zacchei F, Gennari C, Baroni MC, Costi D, Biondi M, Passeri M, Ciacca A, Sbrenna C, Falsettini E, Ventura A (1992) Effects of ipriflavone on bone mass and bone remodeling in patients with established post-menopausal osteoporosis. Curr Ther Res 51:82-91
9. Passeri M, Biondi M, Costi D, Dall'Aglio E, Pedrazzoni M, Bufalino L, Castiglione GN, Abate G (1995) Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. Ital J Mineral Electrolyte Metab 9:137-144
10. Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Felipetto R, Parrini D, Cappelli N, Fioretti P (1993) Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest 16:333-337
11. Agnusdei D, Camporeale A, Gonnelli S, Gennari C, Baroni MC, Passeri M (1992) Short-term treatment of Paget's disease of bone with ipriflavone. Bone Miner 19:S35-S42
12. Mazzuoli GF, Romagnoli E, Carnevale V, Scarda A, Scarnecchia M, Pacitti MT, Rosso R, Minisola V (1992) Effects of ipriflavone on bone remodeling in primary hyperparathyroidism. Bone Miner 19:S27-S33
13. Agnusdei D, Gennari C, Bufalino L (1995) Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporosis Int 5:462-466
14. Mazzuoli GF, Agnusdei D, Crepaldi G, Isaia GC, Ortolani S, Passeri M, Bufalino L, Gennari C (1996) Inhibitory effect of ipriflavone on vertebral bone mass loss in postmenopausal women. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD (eds) Proc 1996 World Congress on Osteoporosis, Amsterdam, 18-23 May. Elsevier, Amsterdam, The Netherlands, pp 281-284
15. Adami S, Bufalino L, Cervetti R, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Serni U, Vecchiet L, Passeri M (1997) Ipriflavone prevents radial bone mass loss in postmenopausal women with low bone mass over 2 years. Osteoporosis Int 7:119-125
16. Gillings D, Koch G (1991) The application of the principle of intention-to-treat analysis of clinical trials. Drug Inform J 25: 411-424
17. Matthews JNS, Altman DG, Campbell MJ, Tayston P (1990) Analysis of serial measurements in medical research. Br Med J 300:230-235
18. Valente M, Bufalino L, Castiglione GN, D'Angelo R, Mancuso A, Galoppi P, Zichella L (1994) Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 54:377-380
19. Melis GB, Paoletti AM, Cagnacci A (1996) Ipriflavone prevents bone loss in postmenopausal women. Menopause 3:27-32
20. Horsman A, Gallagher JC, Simpson M, Nordin BEC (1977) Prospective trial of oestrogen and calcium in postmenopausal women. Br Med J 2:789-792
21. Nilas L, Christiansen C, Rodbro P (1984) Calcium supplementation and postmenopausal bone loss. Br Med J 289:1103-1106
22. Recker RR, Saville PD, Heaney RP (1977) Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 87:649-655
23. Riis B, Thomsen K, Christiansen C (1987) Does calcium supplementation prevent postmenopausal bone loss? N Engl J Med 316:173-177